JP2016530323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530323A5 JP2016530323A5 JP2016542315A JP2016542315A JP2016530323A5 JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5 JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016530323 A5 JP2016530323 A5 JP 2016530323A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- tumor
- antigen
- administered
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876509P | 2013-09-11 | 2013-09-11 | |
| US61/876,509 | 2013-09-11 | ||
| US201461971212P | 2014-03-27 | 2014-03-27 | |
| US61/971,212 | 2014-03-27 | ||
| US201461978401P | 2014-04-11 | 2014-04-11 | |
| US61/978,401 | 2014-04-11 | ||
| US201462003349P | 2014-05-27 | 2014-05-27 | |
| US62/003,349 | 2014-05-27 | ||
| PCT/EP2014/069425 WO2015036499A1 (en) | 2013-09-11 | 2014-09-11 | Anti-b7-h1 antibodies for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Division JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530323A JP2016530323A (ja) | 2016-09-29 |
| JP2016530323A5 true JP2016530323A5 (enExample) | 2017-10-12 |
| JP6550053B2 JP6550053B2 (ja) | 2019-07-24 |
Family
ID=51570487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542315A Active JP6550053B2 (ja) | 2013-09-11 | 2014-09-11 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081639A Pending JP2019163269A (ja) | 2013-09-11 | 2019-04-23 | 腫瘍を治療するための抗ｂ７−ｈ１抗体 |
| JP2020152079A Active JP7119037B2 (ja) | 2013-09-11 | 2020-09-10 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2022021883A Active JP7342167B2 (ja) | 2013-09-11 | 2022-02-16 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
| JP2023139429A Pending JP2023166474A (ja) | 2013-09-11 | 2023-08-30 | 腫瘍を治療するための抗ｂ７－ｈ１抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10336823B2 (enExample) |
| EP (2) | EP3043816B1 (enExample) |
| JP (5) | JP6550053B2 (enExample) |
| KR (5) | KR20240056664A (enExample) |
| CN (2) | CN105873606B (enExample) |
| AU (3) | AU2014320343B2 (enExample) |
| BR (1) | BR112016005303A2 (enExample) |
| CA (1) | CA2923499A1 (enExample) |
| DK (1) | DK3043816T3 (enExample) |
| ES (1) | ES2749744T3 (enExample) |
| HU (1) | HUE046674T2 (enExample) |
| IL (5) | IL321966A (enExample) |
| MX (1) | MX370818B (enExample) |
| NZ (2) | NZ757060A (enExample) |
| PL (1) | PL3043816T3 (enExample) |
| RU (1) | RU2701327C2 (enExample) |
| SA (1) | SA516370713B1 (enExample) |
| TW (1) | TWI643633B (enExample) |
| WO (1) | WO2015036499A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| US20240150469A1 (en) * | 2013-09-11 | 2024-05-09 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| IL321966A (en) * | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| US9885721B2 (en) | 2014-05-29 | 2018-02-06 | Spring Bioscience Corporation | PD-L1 antibodies and uses thereof |
| CA2949327A1 (en) * | 2014-05-29 | 2015-12-03 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| TW201614237A (en) * | 2014-09-05 | 2016-04-16 | Medimmune Ltd | Markers for identifying patients responsive to anti-PD-L1 antibody therapy |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| KR20170132171A (ko) | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 ｐｄ１ ／ ｐｄｌ１ 저해제 |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| CN107530434A (zh) * | 2015-04-23 | 2018-01-02 | 免疫医疗有限公司 | 非小细胞肺癌egfr突变阳性的联合疗法 |
| DK3294770T4 (da) * | 2015-05-12 | 2024-05-21 | Hoffmann La Roche | Terapeutiske og diagnostiske fremgangsmåder til cancer |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| CA3025391A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| US11359017B2 (en) | 2016-07-01 | 2022-06-14 | Tohoku University | Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| ES2977589T3 (es) | 2017-08-18 | 2024-08-27 | Cothera Bioscience Inc | Forma polimórfica de TG02 |
| CN111971059A (zh) * | 2018-01-31 | 2020-11-20 | 细胞基因公司 | 使用过继细胞疗法和检查点抑制剂的组合疗法 |
| WO2019180201A2 (en) * | 2018-03-22 | 2019-09-26 | Keires Ag | Antagonistic antigen binding proteins |
| US20220117938A1 (en) | 2019-01-18 | 2022-04-21 | Dracen Pharmaceuticals, Inc. | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
| CN118267468A (zh) * | 2019-01-25 | 2024-07-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| KR20220009941A (ko) | 2019-03-26 | 2022-01-25 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Stat3의 저분자 분해제 |
| WO2020205467A1 (en) | 2019-03-29 | 2020-10-08 | The Regents Of The University Of Michigan | Stat3 protein degraders |
| US20220304984A1 (en) | 2019-06-12 | 2022-09-29 | Vanderbilt University | Amino acid transport inhibitors and the uses thereof |
| WO2020252336A1 (en) | 2019-06-12 | 2020-12-17 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| EP3989984A4 (en) * | 2019-06-25 | 2024-05-22 | City of Hope | TREATMENT OF PDL1-POSITIVE TUMORS WITH NK CELLS |
| CN115443329A (zh) | 2019-06-27 | 2022-12-06 | 乔治华盛顿大学国会特许非营利公司 | Hdac6激活的巨噬细胞、其组合物及用途 |
| AU2020315401B2 (en) | 2019-07-16 | 2025-05-22 | The Regents Of The University Of Michigan | Imidazopyrimidines as EED inhibitors and the use thereof |
| AU2020336381A1 (en) | 2019-08-27 | 2022-03-03 | The Regents Of The University Of Michigan | Cereblon E3 ligase inhibitors |
| AU2020348849A1 (en) | 2019-09-19 | 2022-04-07 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
| WO2021057836A1 (en) * | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| US12522623B2 (en) | 2020-03-26 | 2026-01-13 | Regents Of The University Of Michigan | Small molecule STAT protein degraders |
| WO2022011205A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| WO2022011204A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Small molecule androgen receptor protein degraders |
| WO2022072820A1 (en) | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| WO2022187423A1 (en) | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
| WO2022187419A1 (en) | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Small molecule degraders of androgen receptor |
| IL306028A (en) * | 2021-03-26 | 2023-11-01 | Astrazeneca Ab | Combined treatment for melanoma |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| JP7663866B2 (ja) | 2023-09-27 | 2025-04-17 | 大日本印刷株式会社 | 積層体及び包装袋 |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
| US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| WO2009089149A1 (en) * | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN101693562A (zh) * | 2009-10-21 | 2010-04-14 | 山东大学 | 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| IL321966A (en) * | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| TW201614237A (en) * | 2014-09-05 | 2016-04-16 | Medimmune Ltd | Markers for identifying patients responsive to anti-PD-L1 antibody therapy |
| EP3220951A1 (en) * | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| US10975155B2 (en) * | 2016-05-13 | 2021-04-13 | Medimmune, Llc | CD40L-Fc fusion polypeptides and methods of use thereof |
-
2014
- 2014-09-11 IL IL321966A patent/IL321966A/en unknown
- 2014-09-11 AU AU2014320343A patent/AU2014320343B2/en active Active
- 2014-09-11 CN CN201480049982.1A patent/CN105873606B/zh active Active
- 2014-09-11 KR KR1020247013414A patent/KR20240056664A/ko active Pending
- 2014-09-11 NZ NZ757060A patent/NZ757060A/en unknown
- 2014-09-11 MX MX2016002826A patent/MX370818B/es active IP Right Grant
- 2014-09-11 EP EP14766962.6A patent/EP3043816B1/en active Active
- 2014-09-11 HU HUE14766962A patent/HUE046674T2/hu unknown
- 2014-09-11 WO PCT/EP2014/069425 patent/WO2015036499A1/en not_active Ceased
- 2014-09-11 KR KR1020257042956A patent/KR20260008188A/ko active Pending
- 2014-09-11 TW TW103131437A patent/TWI643633B/zh active
- 2014-09-11 IL IL313188A patent/IL313188B2/en unknown
- 2014-09-11 NZ NZ718821A patent/NZ718821A/en unknown
- 2014-09-11 US US15/021,161 patent/US10336823B2/en active Active
- 2014-09-11 ES ES14766962T patent/ES2749744T3/es active Active
- 2014-09-11 KR KR1020167007277A patent/KR102329584B1/ko active Active
- 2014-09-11 PL PL14766962T patent/PL3043816T3/pl unknown
- 2014-09-11 CA CA2923499A patent/CA2923499A1/en active Pending
- 2014-09-11 IL IL292193A patent/IL292193B2/en unknown
- 2014-09-11 JP JP2016542315A patent/JP6550053B2/ja active Active
- 2014-09-11 CN CN202011433007.4A patent/CN112546217B/zh active Active
- 2014-09-11 RU RU2016113341A patent/RU2701327C2/ru active
- 2014-09-11 BR BR112016005303A patent/BR112016005303A2/pt not_active Application Discontinuation
- 2014-09-11 KR KR1020227040760A patent/KR102661249B1/ko active Active
- 2014-09-11 EP EP19191552.9A patent/EP3656398A1/en active Pending
- 2014-09-11 KR KR1020217037457A patent/KR20210143932A/ko not_active Ceased
- 2014-09-11 DK DK14766962.6T patent/DK3043816T3/da active
-
2016
- 2016-03-03 IL IL244422A patent/IL244422B/en active IP Right Grant
- 2016-03-10 SA SA516370713A patent/SA516370713B1/ar unknown
-
2019
- 2019-04-23 JP JP2019081639A patent/JP2019163269A/ja active Pending
- 2019-05-21 US US16/418,488 patent/US10829557B2/en active Active
-
2020
- 2020-05-05 IL IL274462A patent/IL274462B/en unknown
- 2020-08-27 AU AU2020223728A patent/AU2020223728B2/en active Active
- 2020-09-10 JP JP2020152079A patent/JP7119037B2/ja active Active
- 2020-10-16 US US17/072,756 patent/US11827706B2/en active Active
-
2022
- 2022-02-16 JP JP2022021883A patent/JP7342167B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139429A patent/JP2023166474A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203898A patent/AU2024203898A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016113341A (ru) | Антитела к b7-h1 для лечения опухолей | |
| JP2016520082A5 (enExample) | ||
| JP2017537090A5 (enExample) | ||
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| JP2022531408A5 (enExample) | ||
| Chami et al. | Radiation and immune checkpoint inhibitors: combination therapy for treatment of hepatocellular carcinoma | |
| JP2022501332A5 (enExample) | ||
| JP2008500964A5 (enExample) | ||
| JP2021511344A5 (enExample) | ||
| US9415078B2 (en) | Method of treating desmocollin-3 expressing cancer with Mycobacterium w | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| JP2018501247A5 (enExample) | ||
| Besse et al. | Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC) | |
| RU2812782C2 (ru) | Способ лечения острого миелоидного лейкоза | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| RU2023133857A (ru) | Антитела к b7-h1 для лечения опухолей | |
| WO2023185720A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| Henry et al. | 325 MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation | |
| CN120605267A (zh) | 双氢青蒿素在制备结直肠癌转移药物方面的应用 | |
| CN119212695A (zh) | 施用用于诱导肿瘤相关抗原的苔藓虫素的方法 | |
| Salnikov et al. | 322 Efficacy of Amanitin Conjugated Chimeric Anti-EpCAM Monoclonal Antibody in Experimental Carcinomas | |
| Grifantini et al. | 324 Monoclonal Antibodies Against Novel Tumor Markers for Diagnostic Prognostic and Predictive Applications | |
| Ciprotti et al. | 323 A Pilot Study of the Safety, Efficacy and Effects On Functional Imaging of the Combination of CG250 and Sunitinib in Patients (pts) with Advanced Renal Cell Carcinoma (RCC) | |
| RU2019129614A (ru) | Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого |